Last10K.com

Vertex Pharmaceuticals Inc Ma (VRTX) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

SEC Filings

VRTX Quarterly Reports

Vertex Pharmaceuticals Inc Ma

CIK: 875320 Ticker: VRTX
Vertex Reports First-Quarter 2020 Financial Results
-Product revenues of $1.52 billion, a 77% increase compared to Q1 2019-
-Company raises revenue guidance; now expects 2020 CF revenues of $5.3 to $5.6 billion-
BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2020 and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues.
"The COVID-19 pandemic has presented unprecedented challenges to societies, communities and businesses around the world, and while these global challenges will continue for some time to come, I am very proud of how Vertex has responded to ensure that we continue to deliver on our mission for patients, keep our employees safe and achieve our business goals," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "Importantly, our business continues to grow, and throughout the first quarter, thousands of patients initiated treatment with our medicines worldwide. The U.S. launch of TRIKAFTA has been remarkable, with the majority of eligible patients having now initiated treatment with this medicine. This strong interest reflects TRIKAFTA's substantial benefits for patients and has resulted in significant increases in revenue to support continued investment in both our internal pipeline and business development efforts to support future growth. Looking ahead, we continue to be differentiated by our focus on serial innovation, investment in transformative medicines aimed at the underlying cause of disease, the breadth of our pipeline and capabilities and our financial strength."

First-Quarter 2020 Financial Highlights
 
Three Months Ended March 31,
 
%
 
2020
 
2019
 
Change
 
(in millions, except per share amounts)
Product revenues, net
$
1,515

 
 
$
857

 
 
77%
TRIKAFTA
$
895

 
 
$

 
 
 
SYMDEKO/SYMKEVI
$
173

 
 
$
320

 
 
 
ORKAMBI
$
234

 
 
$
293

 
 
 
KALYDECO
$
213

 
 
$
244

 
 
 
 
 
 
 
 
 
 
 
 
 
GAAP Operating income
$
720

 
 
$
277

 
 
160%
Non-GAAP Operating income
$
877

 
 
$
377

 
 
133%
 
 
 
 
 
 
 
 
 
 
GAAP Net income
$
603

 
 
$
269

 
 
124%
Non-GAAP Net income
$
674

 
 
$
296

 
 
128%
 
 
 
 
 
 
 
 
 
 
GAAP Net income per share - diluted
$
2.29

 
 
$
1.03

 
 
122%
Non-GAAP Net income per share - diluted
$
2.56

 
 
$
1.14

 
 
125%

1

The following information was filed by Vertex Pharmaceuticals Inc Ma (VRTX) on Wednesday, April 29, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Vertex Pharmaceuticals Inc Ma's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vertex Pharmaceuticals Inc Ma.

Continue

Assess how Vertex Pharmaceuticals Inc Ma's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Vertex Pharmaceuticals Inc Ma's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Legal
M & A
Other
Filter Subcategory:
All
Shares
Expense
Product
Income
Earnings
Other
Inside Vertex Pharmaceuticals Inc Ma's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income
Condensed Consolidated Statements Of Comprehensive Income (Parenthetical)
Condensed Consolidated Statements Of Operations
Condensed Consolidated Statements Of Shareholders' Equity
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) (Details)
Accumulated Other Comprehensive Income (Loss) (Tables)
Additional Cash Flow Information
Additional Cash Flow Information (Details)
Additional Cash Flow Information (Tables)
Basis Of Presentation And Accounting Policies
Basis Of Presentation And Accounting Policies (Details)
Basis Of Presentation And Accounting Policies (Policies)
Collaborative Arrangements
Collaborative Arrangements (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Anti-Dilutive Securities (Details)
Earnings Per Share - Schedule Of Computation (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Details)
Fair Value Measurements - Fair Value Of Contingent Consideration Liabilities (Details)
Fair Value Measurements - Financial Assets And Liabilities Subject To Fair Value Measurements (Details)
Hedging
Hedging (Tables)
Hedging - Cash Flow Hedging Instruments (Details)
Hedging - Derivative Fair Value (Details)
Hedging - Narrative (Details)
Hedging - Notional Amount (Details)
Hedging - Offsetting Derivatives (Details)
Income Taxes
Income Taxes (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Marketable Securities And Equity Investments
Marketable Securities And Equity Investments (Tables)
Marketable Securities And Equity Investments - Additional Information (Details)
Marketable Securities And Equity Investments - Available-For-Sale Debt Securities At Fair Value (Details)
Marketable Securities And Equity Investments - Available-For-Sale Debt Securities By Contractual Maturity (Details)
Marketable Securities And Equity Investments - Summary Of Cash Equivalents And Marketable Securities (Details)
Revenue Recognition
Revenue Recognition (Tables)
Revenue Recognition - Disaggregation Of Revenue (Details)
Revenue Recognition - Narrative (Details)
Stock-Based Compensation Expense And Share Repurchase Programs
Stock-Based Compensation Expense And Share Repurchase Programs (Tables)
Stock-Based Compensation Expense And Share Repurchase Programs - Additional Information (Details)
Stock-Based Compensation Expense And Share Repurchase Programs - Stock Options Outstanding And Exercisable (Details)
Stock-Based Compensation Expense And Share Repurchase Programs - Stock-Based Compensation Expense (Details)

Material Contracts, Statements, Certifications & more

Vertex Pharmaceuticals Inc Ma provided additional information to their SEC Filing as exhibits

Ticker: VRTX
CIK: 875320
Form Type: 10-Q Quarterly Report
Accession Number: 0000875320-20-000019
Submitted to the SEC: Fri May 01 2020 4:37:49 PM EST
Accepted by the SEC: Fri May 01 2020
Period: Tuesday, March 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/vrtx/0000875320-20-000019.htm